Hennion & Walsh Asset Management Inc. Sells 1,206 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Hennion & Walsh Asset Management Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 53.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,047 shares of the biopharmaceutical company’s stock after selling 1,206 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $589,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of REGN. Robeco Institutional Asset Management B.V. lifted its stake in shares of Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock valued at $67,969,000 after purchasing an additional 73,176 shares during the period. CWA Asset Management Group LLC lifted its stake in Regeneron Pharmaceuticals by 12.9% in the third quarter. CWA Asset Management Group LLC now owns 1,615 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 185 shares during the period. Earned Wealth Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $355,000. Fifth Third Wealth Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 1,561 shares of the biopharmaceutical company’s stock worth $878,000 after buying an additional 50 shares during the period. Finally, Moss Adams Wealth Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 5.9% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 1,470 shares of the biopharmaceutical company’s stock worth $827,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on REGN. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Canaccord Genuity Group lifted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Finally, Scotiabank boosted their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $791.05.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,431 shares of company stock valued at $5,733,521 over the last 90 days. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $796.55 on Friday. The stock has a 50-day moving average price of $738.12 and a two-hundred day moving average price of $628.80. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a market cap of $83.72 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 2.16 and a beta of 0.39. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the prior year, the firm earned $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.